MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 407402 | Name: MS417
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MS417, also known as GTPL7512, is a potent and selective BRD4 inhibitor. MS417 inhibits colorectal cancer growth and metastasis. Treatment with inhibitor MS417 potently affects cancer cells, although such effects were not always outright necrosis or apoptosis.

Chemical Structure

MS417
MS417
CAS#916489-36-6

Theoretical Analysis

MedKoo Cat#: 407402

Name: MS417

CAS#: 916489-36-6

Chemical Formula: C20H19ClN4O2S

Exact Mass: 414.0917

Molecular Weight: 414.91

Elemental Analysis: C, 57.90; H, 4.62; Cl, 8.54; N, 13.50; O, 7.71; S, 7.73

Price and Availability

Size Price Availability Quantity
5mg USD 280.00 2 Weeks
25mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MS417; MS-417; MS 417; GTPL7512; GTPL-7512; GTPL 7512.
IUPAC/Chemical Name
methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate
InChi Key
GGRCIHACOIMRKY-HNNXBMFYSA-N
InChi Code
InChI=1S/C20H19ClN4O2S/c1-10-11(2)28-20-17(10)18(13-5-7-14(21)8-6-13)22-15(9-16(26)27-4)19-24-23-12(3)25(19)20/h5-8,15H,9H2,1-4H3/t15-/m0/s1
SMILES Code
CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC)C4=CC=C(C=C4)Cl)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MS417 is a selective BET-specific BRD4 inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM.
In vitro activity:
Consequently, this study performed migration and invasion assay using transwell to verify if MS417 also attenuates the metastatic capability of these lines. After treatment with MS417 for 48 h, cell counts for both HT29 and SW620 reduced significantly compared to control, indicating a significant reduction in cellular movement. The migratory and invasive behavior of HT29 cells was largely curtailed as a result of the addition of MS417. Reference: Int J Mol Sci. 2015 Jan 16;16(1):1928-48. https://pubmed.ncbi.nlm.nih.gov/25603177/
In vivo activity:
This study treated both male db/db and db/m mice with either vehicle or MS417 for a total of 12 weeks. Kidney hypertrophy observed in db/db mice was attenuated by MS417 treatment (Supplementary Table 5). MS417 treatment significantly reduced proteinuria and mesangial expansion in diabetic db/db mice compared with the mice treated with vehicle (Fig. 7E–G). The corresponding target genes of NF-κB and STAT3 that increased in the glomeruli of db/db mice also were suppressed by MS417 treatment (Supplementary Fig. 4A–D). Reference: Diabetes. 2014 Jul;63(7):2440-53. https://pubmed.ncbi.nlm.nih.gov/24608443/
Solvent mg/mL mM
Solubility
Ethanol 50.0 120.51
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 414.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hu Y, Zhou J, Ye F, Xiong H, Peng L, Zheng Z, Xu F, Cui M, Wei C, Wang X, Wang Z, Zhu H, Lee P, Zhou M, Jiang B, Zhang DY. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int J Mol Sci. 2015 Jan 16;16(1):1928-48. doi: 10.3390/ijms16011928. PMID: 25603177; PMCID: PMC4307342. 2. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J, Chuang PY, Ohlmeyer M, He JC, Zhou MM. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. doi: 10.1074/jbc.M112.359505. Epub 2012 May 29. Erratum in: J Biol Chem. 2012 Nov 9;287(46):38956. PMID: 22645123; PMCID: PMC3436579. 3. Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY, He JC. Role of transcription factor acetylation in diabetic kidney disease. Diabetes. 2014 Jul;63(7):2440-53. doi: 10.2337/db13-1810. Epub 2014 Mar 7. PMID: 24608443; PMCID: PMC4066331.
In vitro protocol:
1. Hu Y, Zhou J, Ye F, Xiong H, Peng L, Zheng Z, Xu F, Cui M, Wei C, Wang X, Wang Z, Zhu H, Lee P, Zhou M, Jiang B, Zhang DY. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int J Mol Sci. 2015 Jan 16;16(1):1928-48. doi: 10.3390/ijms16011928. PMID: 25603177; PMCID: PMC4307342. 2. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J, Chuang PY, Ohlmeyer M, He JC, Zhou MM. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. doi: 10.1074/jbc.M112.359505. Epub 2012 May 29. Erratum in: J Biol Chem. 2012 Nov 9;287(46):38956. PMID: 22645123; PMCID: PMC3436579.
In vivo protocol:
1. Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY, He JC. Role of transcription factor acetylation in diabetic kidney disease. Diabetes. 2014 Jul;63(7):2440-53. doi: 10.2337/db13-1810. Epub 2014 Mar 7. PMID: 24608443; PMCID: PMC4066331. 2. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J, Chuang PY, Ohlmeyer M, He JC, Zhou MM. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. doi: 10.1074/jbc.M112.359505. Epub 2012 May 29. Erratum in: J Biol Chem. 2012 Nov 9;287(46):38956. PMID: 22645123; PMCID: PMC3436579.
1: Hu Y, Zhou J, Ye F, Xiong H, Peng L, Zheng Z, Xu F, Cui M, Wei C, Wang X, Wang Z, Zhu H, Lee P, Zhou M, Jiang B, Zhang DY. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int J Mol Sci. 2015 Jan 16;16(1):1928-48. doi: 10.3390/ijms16011928. PubMed PMID: 25603177; PubMed Central PMCID: PMC4307342. 2: Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY, He JC. Role of transcription factor acetylation in diabetic kidney disease. Diabetes. 2014 Jul;63(7):2440-53. doi: 10.2337/db13-1810. Epub 2014 Mar 7. PubMed PMID: 24608443; PubMed Central PMCID: PMC4066331. 3: Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle. 2013 Feb 1;12(3):452-62. doi: 10.4161/cc.23309. Epub 2012 Feb 1. PubMed PMID: 23255218; PubMed Central PMCID: PMC3587446. 4: Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J, Chuang PY, Ohlmeyer M, He JC, Zhou MM. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. doi: 10.1074/jbc.M112.359505. Epub 2012 May 29. Erratum in: J Biol Chem. 2012 Nov 9;287(46):38956. PubMed PMID: 22645123; PubMed Central PMCID: PMC3436579. 5: Sayles M, Winter IM. Ambiguous pitch and the temporal representation of inharmonic iterated rippled noise in the ventral cochlear nucleus. J Neurosci. 2008 Nov 12;28(46):11925-38. doi: 10.1523/JNEUROSCI.3137-08.2008. PubMed PMID: 19005058. 6: von Lackum K, Miller JC, Bykowski T, Riley SP, Woodman ME, Brade V, Kraiczy P, Stevenson B, Wallich R. Borrelia burgdorferi regulates expression of complement regulator-acquiring surface protein 1 during the mammal-tick infection cycle. Infect Immun. 2005 Nov;73(11):7398-405. PubMed PMID: 16239539; PubMed Central PMCID: PMC1273877.